Literature DB >> 9145904

Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.

F J Caballero-Granado, P Viciana, E Cordero, M J Gómez-Vera, M del Nozal, L F López-Cortés.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9145904      PMCID: PMC163885     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

1.  Drug points: severe ergotism associated with interaction between ritonavir and ergotamine.

Authors:  L Liaudet; T Buclin; C Jaccard; P Eckert
Journal:  BMJ       Date:  1999-03-20

2.  Hospitalization due to adverse drug reactions and drug interactions before and after HAART.

Authors:  M M Foisy; K Gough; C M Quan; K Harris; D Ibanez; A Phillips
Journal:  Can J Infect Dis       Date:  2000-07

Review 3.  Drug interactions of HIV protease inhibitors.

Authors:  L I Malaty; J J Kuper
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

Review 4.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 5.  Mycotoxins.

Authors:  J W Bennett; M Klich
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 6.  Cabergoline: a review of its use in the inhibition of lactation for women living with HIV.

Authors:  Karen J Tulloch; Philippe Dodin; Fannie Tremblay-Racine; Chelsea Elwood; Deborah Money; Isabelle Boucoiran
Journal:  J Int AIDS Soc       Date:  2019-06       Impact factor: 5.396

7.  Use of lopinavir/ritonavir associated with ergotamine resulting in foot amputation: brief communication.

Authors:  Fernando Raphael de Almeida Ferry; Guilherme Almeida Rosa Da Silva; Rogerio Neves Motta; Ricardo de Souza Carvalho; Carlos Alberto Morais De Sá
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 May-Jun       Impact factor: 1.846

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.